1

Welcome and role call

BGO, all

2

 Allergy/hypersensitivity editorial guidelines

BGO

• Editorial guidelines based on approved model for review

Few additional edits as suggested added. Intolerance to substance now included in this document

3

Concurrent vs. co-occurrent

BGO

See comments

1. 351 concepts use co-occurrent with in FSN

2. 3 concept uses concurrent with in FSN

3. SCA editor spell checker prefers concurrent

Suggest we use co-occurrent with as all documentation thus far uses this

4

Complications and sequela

BGO

• Editorial guidelines review

Few additional edits following discussion with Phil Brown and James Case

5

During and/or after

BGO

• Should the proposed during and/or after role be used for all procedure complications for which a temporal relationship is not specified?

• Consensus was that for combined disorders/disorders with procedures for which a temporal sequence was not specified between components to not use during and/or after.

• Bruce Goldberg to clarify with Ed Cheetham initial use case for this proposed role

6

Modeling of CVAs due to thrombosis/embolus - follow-up

BGO

• Revised model for review

• Proposed model was to use specific artery/vein thrombosis concepts as value of due to along with an associated morphology of 78195007 |Occlusive thrombus (morphologic abnormality). Issue raised that occlusive thrombus (morphologic abnormality) as residing in role group 0 would refer to theCVA rather than the thrombosis. Suggested solution is to create specific occlusive artery/vein thrombosis concepts as the value of due to

• Bruce Goldberg to test above in SCA tool

7

AOB, adjourn

ALL

• Next meeting July 10, 2017 20:00 UTC